HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fogelman, I. Articles by Greig, W. R. Search for Related Content PubMed PubMed Citation Articles by Fogelman, I. Articles by Greig, W. R.

The Use of Whole-Body Retention of Tc-99m Diphosphonate in the Diagnosis of Metabolic Bone Disease

Royal Infirmary, Glasgow, G4 OSF, Scotland

Correspondence: For reprints contact: Ignac Fogelman, Dept. of Nuclear Medicine, Royal Infirmary, Glasgow G4 OSF, Scotland.

ABSTRACT

The limited role of bone scanning in the diagnosis of metabolic bone disease might be considerably improved by accurate quantification of skeletal uptake of the radiopharmaceutical. Using a standard shadow-shield whole-body monitor, we have measured whole-body retention (WBR) of Tc-99m HEDP up to 24 hr in 11 patients with renal osteodystrophy (mean WBR 88.6% at 24 hr); in ten patients with Paget's disease (mean 56.9%); in seven patients with osteomalacia (mean 40.7%); in five patients with primary hyperparathyroidism (mean 50.7%); in four patients with osteoporosis (mean 21.2%); and in 12 normals (mean 19.2%). The osteoporotic group could not be differentiated from the normal group, but the other groups were significantly different from the normal group at 24 hr (p < 0.002), and each individual result for the 24-hr WBR of Tc-99m HEDP in these groups lay outside our normal range. This test may, therefore, provide a sensitive means of detecting conditions with increased bone turnover. We obtained measurements of plasma activity of Tc-99m HEDP in these patients up to 24 hr, and 4-hr bone to soft-tissue ratios from bone scan images, but little additional information resulted.

FOOTNOTES

^* Address: Dept. of Nuclear Medicine and Division of Clinical Oncology, University of Wisconsin Hospitals, Madison, WI 53706.

This article has been cited by other articles:

				H. Jacobsson Short-time Ingestion of Colas Influences the Activity Distribution at Bone Scintigraphy: Experimental Studies in the Mouse J. Am. Coll. Nutr., April 1, 2008; 27(2): 332 - 336. [Abstract] [Full Text] [PDF]

				A. E.B. Moore, G. M. Blake, and I. Fogelman Quantitative Measurements of Bone Remodeling Using 99mTc-Methylene Diphosphonate Bone Scans and Blood Sampling J. Nucl. Med., March 1, 2008; 49(3): 375 - 382. [Abstract] [Full Text] [PDF]

				D.B. Kimmel Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates J. Dent. Res., November 1, 2007; 86(11): 1022 - 1033. [Abstract] [Full Text] [PDF]

				R. G. G. Russell Bisphosphonates: Mode of Action and Pharmacology Pediatrics, March 1, 2007; 119(Supplement_2): S150 - S162. [Abstract] [Full Text] [PDF]

				A. E.B. Moore, G. M. Blake, and I. Fogelman Validation of a Blood-Sampling Method for the Measurement of 99mTc-Methylene Diphosphonate Skeletal Plasma Clearance J. Nucl. Med., April 1, 2006; 47(4): 581 - 586. [Abstract] [Full Text] [PDF]

				A. E.B. Moore, S. F. Hain, G. M. Blake, and I. Fogelman Validation of Ultrafiltration as a Method of Measuring Free 99mTc-MDP J. Nucl. Med., June 1, 2003; 44(6): 891 - 897. [Abstract] [Full Text] [PDF]

				G. M. Blake, S.-J. Park-Holohan, and I. Fogelman Quantitative Studies of Bone in Postmenopausal Women Using 18F-Fluoride and 99mTc-Methylene Diphosphonate J. Nucl. Med., March 1, 2002; 43(3): 338 - 345. [Abstract] [Full Text] [PDF]

				W. Brenner, W. U. Kampen, A. M. Kampen, and E. Henze Skeletal Uptake and Soft-Tissue Retention of 186Re-HEDP and 153Sm-EDTMP in Patients with Metastatic Bone Disease J. Nucl. Med., February 1, 2001; 42(2): 230 - 236. [Abstract] [Full Text]